John M Powers
Overview
Explore the profile of John M Powers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
189
Citations
1728
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schafer A, Leist S, Powers J, Baric R
Sci Transl Med
. 2024 Nov;
16(773):eado2104.
PMID: 39536118
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV 2) pandemic has caused more than 7 million deaths globally. Despite the presence of infection- and vaccine-induced immunity, SARS-CoV-2 infections remain a...
2.
Weber W, Andoh T, Kreklywich C, Streblow Z, Denton M, Streblow M, et al.
Vaccines (Basel)
. 2024 Sep;
12(9).
PMID: 39340002
Chikungunya virus (CHIKV) is a pathogenic arthritogenic alphavirus responsible for large-scale human epidemics for which a vaccine was recently approved for use. Mayaro virus (MAYV) is a related emerging alphavirus...
3.
Powers J, Briggs H, Campbell D
New Phytol
. 2024 Sep;
245(1):332-346.
PMID: 39329349
Climate change is disrupting floral traits that mediate mutualistic and antagonistic species interactions. Plastic responses of these traits to multiple shifting conditions may be adaptive, depending on natural selection in...
4.
Voss W, Mallory M, Byrne P, Marchioni J, Knudson S, Powers J, et al.
Cell Rep Med
. 2024 Aug;
5(8):101668.
PMID: 39094579
We describe the molecular-level composition of polyclonal immunoglobulin G (IgG) anti-spike antibodies from ancestral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, vaccination, or their combination ("hybrid immunity") at monoclonal...
5.
Hendricks G, Grigoryan L, Navarro M, Catanzaro N, Hubbard M, Powers J, et al.
bioRxiv
. 2024 Aug;
PMID: 39091730
Both protein nanoparticle and mRNA vaccines were clinically de-risked during the COVID-19 pandemic. These vaccine modalities have complementary strengths: antigen display on protein nanoparticles can enhance the magnitude, quality, and...
6.
Lee J, Stewart C, Schafer A, Leaf E, Park Y, Asarnow D, et al.
Nat Commun
. 2024 Jun;
15(1):5496.
PMID: 38944664
Evolution of SARS-CoV-2 alters the antigenicity of the immunodominant spike (S) receptor-binding domain and N-terminal domain, undermining the efficacy of vaccines and antibody therapies. To overcome this challenge, we set...
7.
Pierre C, Adams L, Higgins J, Anasti K, Goodman D, Mielke D, et al.
PLoS Pathog
. 2024 Jun;
20(6):e1011569.
PMID: 38900807
Antibodies perform both neutralizing and non-neutralizing effector functions that protect against certain pathogen-induced diseases. A human antibody directed at the SARS-CoV-2 Spike N-terminal domain (NTD), DH1052, was recently shown to...
8.
Mallory M, Munt J, Narowski T, Castillo I, Cuadra E, Pisanic N, et al.
Sci Adv
. 2024 Jun;
10(24):eadi1379.
PMID: 38865463
The recommended COVID-19 booster vaccine uptake is low. At-home lateral flow assay (LFA) antigen tests are widely accepted for detecting infection during the pandemic. Here, we present the feasibility and...
9.
Dillard J, Taft-Benz S, Knight A, Anderson E, Pressey K, Parotti B, et al.
Nat Commun
. 2024 May;
15(1):3738.
PMID: 38702297
Whole virus-based inactivated SARS-CoV-2 vaccines adjuvanted with aluminum hydroxide have been critical to the COVID-19 pandemic response. Although these vaccines are protective against homologous coronavirus infection, the emergence of novel...
10.
Terry D, Burgess J, Powers J, Blatz M
Compend Contin Educ Dent
. 2024 Apr;
45(4):184-190.
PMID: 38622077
Post and core systems have long been used in dentistry for the purposes of replacing missing coronal tooth structure, retaining the core, and providing sufficient retention and resistance form to...